Logo image of RNAC

CARTESIAN THERAPEUTICS INC (RNAC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RNAC - US8162123025 - Common Stock

6.88 USD
-0.02 (-0.29%)
Last: 12/5/2025, 8:00:01 PM
6.88 USD
0 (0%)
After Hours: 12/5/2025, 8:00:01 PM
Fundamental Rating

3

Overall RNAC gets a fundamental rating of 3 out of 10. We evaluated RNAC against 531 industry peers in the Biotechnology industry. While RNAC seems to be doing ok healthwise, there are quite some concerns on its profitability. RNAC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RNAC has reported negative net income.
RNAC had a negative operating cash flow in the past year.
RNAC had negative earnings in 4 of the past 5 years.
In the past 5 years RNAC reported 4 times negative operating cash flow.
RNAC Yearly Net Income VS EBIT VS OCF VS FCFRNAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

RNAC has a Return On Assets of -13.58%. This is amongst the best in the industry. RNAC outperforms 81.12% of its industry peers.
Industry RankSector Rank
ROA -13.58%
ROE N/A
ROIC N/A
ROA(3y)-22.83%
ROA(5y)-25.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNAC Yearly ROA, ROE, ROICRNAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RNAC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNAC Yearly Profit, Operating, Gross MarginsRNAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

4

2. Health

2.1 Basic Checks

RNAC does not have a ROIC to compare to the WACC, probably because it is not profitable.
RNAC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RNAC has more shares outstanding
There is no outstanding debt for RNAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNAC Yearly Shares OutstandingRNAC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
RNAC Yearly Total Debt VS Total AssetsRNAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -2.79, we must say that RNAC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.79, RNAC is in line with its industry, outperforming 45.42% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.79
ROIC/WACCN/A
WACC8.78%
RNAC Yearly LT Debt VS Equity VS FCFRNAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

A Current Ratio of 10.67 indicates that RNAC has no problem at all paying its short term obligations.
RNAC's Current ratio of 10.67 is amongst the best of the industry. RNAC outperforms 83.36% of its industry peers.
RNAC has a Quick Ratio of 10.67. This indicates that RNAC is financially healthy and has no problem in meeting its short term obligations.
RNAC has a better Quick ratio (10.67) than 83.36% of its industry peers.
Industry RankSector Rank
Current Ratio 10.67
Quick Ratio 10.67
RNAC Yearly Current Assets VS Current LiabilitesRNAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

RNAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.70%, which is quite impressive.
The Revenue for RNAC has decreased by -95.98% in the past year. This is quite bad
RNAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.27% yearly.
EPS 1Y (TTM)83.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.12%
Revenue 1Y (TTM)-95.98%
Revenue growth 3Y-22.95%
Revenue growth 5Y42.27%
Sales Q2Q%16.8%

3.2 Future

The Earnings Per Share is expected to grow by 11.97% on average over the next years. This is quite good.
The Revenue is expected to grow by 17.87% on average over the next years. This is quite good.
EPS Next Y79.52%
EPS Next 2Y30.6%
EPS Next 3Y19%
EPS Next 5Y11.97%
Revenue Next Year-95.02%
Revenue Next 2Y-87%
Revenue Next 3Y-71.44%
Revenue Next 5Y17.87%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RNAC Yearly Revenue VS EstimatesRNAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
RNAC Yearly EPS VS EstimatesRNAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RNAC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNAC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNAC Price Earnings VS Forward Price EarningsRNAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNAC Per share dataRNAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

RNAC's earnings are expected to grow with 19.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.6%
EPS Next 3Y19%

More info and screens

0

5. Dividend

5.1 Amount

RNAC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARTESIAN THERAPEUTICS INC

NASDAQ:RNAC (12/5/2025, 8:00:01 PM)

After market: 6.88 0 (0%)

6.88

-0.02 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst Owners24.01%
Inst Owner Change-6.28%
Ins Owners39.65%
Ins Owner Change-0.13%
Market Cap178.88M
Revenue(TTM)1.93M
Net Income(TTM)-50.61M
Analysts82.67
Price Target35.99 (423.11%)
Short Float %19.44%
Short Ratio16.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)50.2%
Min EPS beat(2)-60.11%
Max EPS beat(2)160.52%
EPS beat(4)3
Avg EPS beat(4)33.41%
Min EPS beat(4)-60.11%
Max EPS beat(4)160.52%
EPS beat(8)4
Avg EPS beat(8)-112.56%
EPS beat(12)6
Avg EPS beat(12)-65.9%
EPS beat(16)9
Avg EPS beat(16)-57.78%
Revenue beat(2)1
Avg Revenue beat(2)8.97%
Min Revenue beat(2)-64.04%
Max Revenue beat(2)81.99%
Revenue beat(4)2
Avg Revenue beat(4)6.99%
Min Revenue beat(4)-64.04%
Max Revenue beat(4)81.99%
Revenue beat(8)5
Avg Revenue beat(8)195.9%
Revenue beat(12)6
Avg Revenue beat(12)121.23%
Revenue beat(16)9
Avg Revenue beat(16)114.73%
PT rev (1m)-3.14%
PT rev (3m)-3.14%
EPS NQ rev (1m)20.78%
EPS NQ rev (3m)18.02%
EPS NY rev (1m)-16.95%
EPS NY rev (3m)-9.95%
Revenue NQ rev (1m)-76.35%
Revenue NQ rev (3m)-75.15%
Revenue NY rev (1m)6.2%
Revenue NY rev (3m)6.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 92.83
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-3.44
Fwd EYN/A
FCF(TTM)-2.65
FCFYN/A
OCF(TTM)-2.43
OCFYN/A
SpS0.07
BVpS-1.38
TBVpS-9.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.58%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.83%
ROA(5y)-25.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 199.75%
Cap/Sales 294.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.67
Quick Ratio 10.67
Altman-Z -2.79
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)302.59%
Cap/Depr(5y)221.09%
Cap/Sales(3y)8.41%
Cap/Sales(5y)6.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.12%
EPS Next Y79.52%
EPS Next 2Y30.6%
EPS Next 3Y19%
EPS Next 5Y11.97%
Revenue 1Y (TTM)-95.98%
Revenue growth 3Y-22.95%
Revenue growth 5Y42.27%
Sales Q2Q%16.8%
Revenue Next Year-95.02%
Revenue Next 2Y-87%
Revenue Next 3Y-71.44%
Revenue Next 5Y17.87%
EBIT growth 1Y-58.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y-65.62%
EBIT Next 5Y-21.06%
FCF growth 1Y-71.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.18%
OCF growth 3YN/A
OCF growth 5YN/A

CARTESIAN THERAPEUTICS INC / RNAC FAQ

What is the ChartMill fundamental rating of CARTESIAN THERAPEUTICS INC (RNAC) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RNAC.


What is the valuation status for RNAC stock?

ChartMill assigns a valuation rating of 0 / 10 to CARTESIAN THERAPEUTICS INC (RNAC). This can be considered as Overvalued.


How profitable is CARTESIAN THERAPEUTICS INC (RNAC) stock?

CARTESIAN THERAPEUTICS INC (RNAC) has a profitability rating of 1 / 10.